Parabilis Medicines, Inc.(PBLS)

Biotechnology · Cambridge, MA

$28.52-1.01 (-3.42%)

Delayed quote: Oct 6, 2026, 12:55 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:57:53.409Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:57:53.409Z.

Quote observation: 2026-10-06T16:55:12.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: N/A
Quote market capitalization: 3,324,421,536
Total debt · period ending 2026-06-30: 47,512,000
Cash · period ending 2026-06-30: 1,087,060,000

FMP input reference: 66afd7ad6fe085f612ae866be6517f9e897c4fba6e73e474a8e5d595bf17d99d

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PBLS EBITDA Yield Metrics

EBITDA YIELD

N/A

PBLS Competitors' EBITDA Yield

PBLS

Parabilis Medicines, Inc.

Current

Market Cap

$3.32B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACAD

Acadia Pharmaceuticals Inc.

vs PBLS

Market Cap

$3.39B

EBITDA Yield

3.19%

TTM Avg

4.14%

3Y Avg

4.45%

5Y Avg

4.45%

CDNA

CareDx, Inc

vs PBLS

Market Cap

$3.40B

EBITDA Yield

0.51%

TTM Avg

4.11%

3Y Avg

5.67%

5Y Avg

5.67%

PLSE

Pulse Biosciences, Inc.

vs PBLS

Market Cap

$3.41B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XENE

Xenon Pharmaceuticals Inc.

vs PBLS

Market Cap

$3.48B

EBITDA Yield

N/A

TTM Avg

9.48%

3Y Avg

9.54%

5Y Avg

9.54%

CELC

Celcuity Inc.

vs PBLS

Market Cap

$3.49B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IDYA

IDEAYA Biosciences, Inc.

vs PBLS

Market Cap

$3.49B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DNLI

Denali Therapeutics Inc.

vs PBLS

Market Cap

$3.09B

EBITDA Yield

N/A

TTM Avg

0.89%

3Y Avg

0.89%

5Y Avg

0.89%

IRTC

iRhythm Technologies, Inc.

vs PBLS

Market Cap

$3.55B

EBITDA Yield

0.35%

TTM Avg

0.19%

3Y Avg

0.19%

5Y Avg

0.19%

ARQT

Arcutis Biotherapeutics, Inc.

vs PBLS

Market Cap

$3.04B

EBITDA Yield

1.19%

TTM Avg

0.54%

3Y Avg

0.54%

5Y Avg

0.54%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Parabilis Medicines, Inc. (PBLS)	$3.32B	N/A	N/A	N/A	N/A
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.39B	3.19%	4.14%	4.45%	4.45%
CareDx, Inc (CDNA)vs ›	$3.40B	0.51%	4.11%	5.67%	5.67%
Pulse Biosciences, Inc. (PLSE)vs ›	$3.41B	N/A	N/A	N/A	N/A
Xenon Pharmaceuticals Inc. (XENE)vs ›	$3.48B	N/A	9.48%	9.54%	9.54%
Celcuity Inc. (CELC)vs ›	$3.49B	N/A	N/A	N/A	N/A
IDEAYA Biosciences, Inc. (IDYA)vs ›	$3.49B	N/A	N/A	N/A	N/A
Denali Therapeutics Inc. (DNLI)vs ›	$3.09B	N/A	0.89%	0.89%	0.89%
iRhythm Technologies, Inc. (IRTC)vs ›	$3.55B	0.35%	0.19%	0.19%	0.19%
Arcutis Biotherapeutics, Inc. (ARQT)vs ›	$3.04B	1.19%	0.54%	0.54%	0.54%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

PBLS EBITDA Yield Metrics

PBLS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics